Combining Narrowband UVB with Topical and Systemic Treatments to Maximize Vitiligo Repigmentation

The speaker argued that narrowband UVB works best for vitiligo when combined with topical or systemic therapies, rather than used alone, to maximize repigmentation. They reviewed practical UVB protocols, recommending narrowband UVB about three times weekly when possible, starting around 200 mJ/cm² and increasing doses gradually, with treatment assessment after 18–36 sessions and typically at least 48 sessions, sometimes up to 72. The talk emphasized shared decision-making and tailoring treatment to disease activity and affected areas. For stabilization, topical corticosteroids, calcineurin inhibitors, and topical ruxolitinib can be used, but for repigmentation, combining these with UVB gives superior outcomes. Evidence cited included a randomized trial showing better results with topical steroids plus UVB than UVB alone, meta-analysis data supporting calcineurin inhibitors plus UVB, and an open-label ruxolitinib study where adding UVB improved facial and total body response rates. Systemic combinations were also highlighted: antioxidant therapy plus UVB improved pigmentation compared with UVB alone, and mini-pulse systemic steroids helped control active disease and may enhance repigmentation when combined with UVB. Limited retrospective data suggested methotrexate plus UVB may outperform systemic treatment without UVB. The speaker also discussed emerging JAK inhibitor strategies, including ritlecitinib, upadacitinib, and baricitinib, with early studies suggesting added benefit from UVB, especially in active or extensive vitiligo. The conclusion was that narrowband UVB combined with topical or systemic immunomodulators is currently the gold standard for achieving maximal repigmentation, with the longer-term goal of maintaining stability using lower-intensity treatment.